LG Chem Life Sciences Announces First Participant Dosed in First-in-Human Study of SSAO Inhibitor LG00303174 in the United States
23.2.2021 01:33:00 EET | Business Wire | Press release
LG Chem Life Sciences (“LG Chem”) today announced the first healthy adult volunteer has been safely dosed in the phase I study of LG00303174 being run in the US.
LG Chem licensed LG00303174 (TT-01025) from TransThera Biosciences Co. Ltd. (“TransThera”), a clinical-stage biotechnology company based in Nanjing, China. LG Chem had entered into an exclusive license agreement with TransThera in August 2020 to research, develop, manufacture, and commercialize LG00303174 in the world except China and Japan.
LG00303174 is a potential best-in-class novel SSAO/VAP-1 inhibitor, currently being developed for the treatment of chronic inflammatory diseases, including non-alcoholic steatohepatitis (NASH). The phase 1 study is currently being conducted within the U.S. and approximately 64 subjects are expected to be enrolled.
“The commencement of this study is a significant landmark for LG Chem as we are determined to address the clear unmet needs of those with metabolic disease,” said Adam Benson, Director of Clinical Development of LG Chem Life Sciences Innovation Center in Cambridge, MA. “NASH to this day remains an elusive target. We feel strongly that LG00303174 has shown, in pre-clinical models, to have a strong safety profile, and as an oral therapy, has the potential to address a clear need in a disease that is becoming increasingly burdensome to our healthcare system.”
Dr. Frank Wu, CEO of TransThera, commented: “We congratulate LG Chem team on the rapid implementation of FIH trial in the United States, which marks a key milestone for this collaboration program.”
According to Dr. Jeewoong Son, President of LG Chem Life Sciences in Seoul, Korea, the fast and efficient implementation of this phase 1 study “is a testament to our clinical development capabilities of the LG Chem Life Sciences Innovation Center in Cambridge as a center of excellence to enrich and forward our development pipeline.”
About LG Chem Life Sciences
LG Chem Life Sciences is a business division within LG Chem, engaged in the development, manufacturing, as well as commercializing pharmaceutical products globally. LG Chem Life Sciences seeks to expand and make global presence by focusing on key core therapeutic areas of Immunology, Oncology, and Metabolic Diseases (specifically, diabetes and related metabolic diseases). To achieve such, its strategy is to actively pursue global collaboration encompassing from asset-centric to strategic investment and collaboration.
LG Chem Life Sciences Innovation Center: innovation.lgchem.com
About TransThera Biosciences
TransThera Biosciences is a clinical-stage biotechnology company dedicated to developing innovative therapeutics to target diseases with major unmet medical needs via internal research platform and open innovation. TransThera's current portfolio covers therapeutic areas such as oncology, cardiovascular, and inflammatory diseases. For more information, please visit www.transtherabio.com.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20210222005934/en/
Contact information
Media (Jiin Chung): media.cbl@lgchem.com
General Inquiries: contact.cbl@lgchem.com
Partners: partners.cbl@lgchem.com
About Business Wire
For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Doha Debates Podcast Returns for a New Season Exploring the Ideas Shaping Our World23.9.2026 20:29:00 EEST | Press release
Qatar Foundation’s Doha Debates has launched a new season of the Doha Debates Podcast, with 20 episodes airing weekly through February 16, 2027. The series brings leading global thinkers together to debate some of the world’s most complex and challenging issues. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923050361/en/ Doha Debates Podcast Returns for a New Season (Photo: AETOSWire) The podcast carries forward themes from its flagship debates and town halls through long-form conversations, reflecting Doha Debates’ commitment to open, truth-seeking dialogue exploring global issues with depth, nuance and respect for diverse perspectives. The opening episode, “Will China or the West lead the world into the future?” moderated by Soraya Salam, brings together Renata Ávila, CEO of the Open Knowledge Foundation; Arnaud Bertrand, entrepreneur; Isabel Hilton, visiting professor at the Lau China Institute, King's College, London
Dryad Wins International XPRIZE Wildfire Award for Autonomous Wildfire Detection and Suppression23.9.2026 20:00:00 EEST | Press release
Dryad Networks, a leader in ultra-early wildfire detection, today announced it has been awarded $800,000 in the XPRIZE Wildfire competition for its performance in the Autonomous Wildfire Response finals in Alaska. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923024178/en/ Silvaguard Observation and Suppression drone and Hangar Dryad advanced from an original field of approximately 300 entrants in the four-year competition. In June 2026, three finalists were challenged to autonomously detect and completely suppress a high-risk wildfire within 10 minutes of ignition across 1,000 km² of Alaskan wilderness, leaving any decoy fires untouched. It was the most demanding live test to date of what it will take to stop a destructive fire before it grows out of control. During the tests, the Dryad’s Silvanet sensor network successfully detected and verified target fire in 12 minutes or less and autonomously launched a response, ig
SES Appoints Michel Scholer to Board of Directors23.9.2026 19:54:00 EEST | Press release
SES today announced the appointment of Mr. Michel Scholer, Secretary General of the Luxembourg Government and Chief of Staff to the Prime Minister, to its Board of Directors effective immediately. This appointment is part of SES’s Board succession planning and ongoing commitment to regularly review and strengthen the composition of its Board with diverse expertise and industry experience, ensuring the company is well positioned for future growth and value creation. Prior to his current role with the Luxembourg Government, Mr. Scholer served as a Senior Adviser to the International Monetary Fund, and with the Ministry of Finance, Luxembourg. He was nominated for the SES Board of Directors by the Government of the Grandy Duchy of Luxembourg. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, bus
Future Health - A Global Initiative by Abu Dhabi: New Analysis Estimates Modifiable Health Risks Represent $16.4 Trillion Annual Global GDP Opportunity in 205023.9.2026 19:50:00 EEST | Press release
Addressingbehavioural, metabolic and environmental health risks could generate an estimated $16.4 trillion in annual global GDP uplift in 2050. These findings are presented in The Future of Healthy Living: A $16.4 Trillion Opportunity, a new whitepaper co-authored by Future Health – A Global Initiative by Abu Dhabi, the McKinsey Health Institute (MHI) and Healthy Living at the Department of Health – Abu Dhabi, and released on the sidelines of the 81st Session of the United Nations General Assembly (UNGA 81) in New York. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260923530109/en/ A new whitepaper by Future Health – A Global Initiative by Abu Dhabi, in collaboration with the McKinsey Health Institute, estimates that eliminating modifiable health risks could deliver substantial health and economic benefits The publication comes as governments look to translate the UN Political Declaration on Noncommunicable Diseases and Men
SES Confirms Interim Dividend of EUR 0.2523.9.2026 19:46:00 EEST | Press release
The SES Board of Directors has approved the payment of an interim dividend of EUR 0.25 per A-share (EUR 0.10 per B-share) to be paid to shareholders on October 15, 2026, in line with SES’s commitment to shareholder returns. The interim dividend to be paid in October 2026 will be followed, subject to financial results and shareholder approval, by the payment of a final dividend of at least EUR 0.25 per A-share (EUR 0.10 per B-share) in May 2027. Follow us on: LinkedIn | Facebook | YouTube | X | Instagram Read our Blogs > Visit the Media Gallery > About SES At SES, we believe that space has the power to make a difference. That’s why we design space solutions that help governments protect, businesses grow, and people stay connected—no matter where they are. With integrated multi-orbit satellites and our global terrestrial network, we deliver resilient, seamless connectivity and the highest quality video content to those shaping what’s next. Following our Intelsat acquisition, we now offer
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom